Stock listing

NASDAQ:TYRA Tyra Biosciences, Inc. Stock

Home listing (NASDAQ) of Tyra Biosciences, Inc.

Follow Tyra Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TYRA

$19.04 USD +0.34 (+1.8%)

Close on Oct 15, 2026

Tyra Biosciences, Inc. logo
Ticker
NASDAQ:TYRA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Sep 14, 2026

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

Sep 9, 2026

Tyra Biosciences to Present at the Cantor Global Healthcare Conference

Sep 8, 2026

Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

Sep 4, 2026

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Aug 4, 2026

TYRA Biosciences and BCAN establish May 21 as upper tract urothelial cancer (UTUC) awareness day

May 21, 2026

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

May 13, 2026

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Apr 17, 2026

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Mar 2, 2026

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

Feb 23, 2026

All Tyra Biosciences, Inc. news

Financings

  • Public offering of common stock and pre-funded warrants

    Sep 14, 2026

    Announced: about US$400M · US$22.03 a share · Jefferies +7

    Dealers: Jefferies (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), Barclays (co-lead), William Blair (co-lead), Wedbush PacGrow, Raymond James, Oppenheimer & Co.

    Buyers: RA Capital Management (led the offering); Invus; Commodore Capital; BVF Partners; Janus Henderson Investors; Trails Edge Capital Partners; Integral Health Asset Management; TCGX; StemPoint Capital LP

    Use of proceeds: Advance dabogratinib development in LG-UTUC, IR NMIBC and achondroplasia, preclinical and discovery programs, working capital and general corporate purposes

    Announced Sep 14, 2026

Read by 6ix AI from the company's releases

Decks

Tyra Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 65 in all · newest Sep 14, 2026 · oldest 2021
Decks
3 decks · latest September 2026

Where Tyra Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TYRA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TYRABOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Tyra Biosciences, Inc.